Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fx-5A in Healthy Volunteers
NCT04216342Phase 1Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Sep 2021
- Primary completion
- Jun 2027
- Modality
- Peptide Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fx-5A peptide complex in cardiovascular disease (CVD), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Safety and Tolerability at 28 days. Started Sep 2021; status: recruiting.
02
Drugs
Fx-5A peptide complex
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT04216342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04216342.